Drupal.behaviors.print = function(context) {window.print();window.close();}>
Arrowhead Invests $1M in Calando Subsidiary
January 20, 2011
Arrowhead Invests $1M in Calando Subsidiary
The companies also converted roughly $8 million in Calando debt it owed Arrowhead into equity.
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Arrowhead Names HBV as Next RNAi Program While It Consolidates Operations
February 16, 2012 / Gene Silencing News
Arrowhead Reports Increased Fiscal Q4 Losses on Higher Expenses
December 22, 2011 / Gene Silencing News
Arrowhead to Move Calando Cancer Drug into Phase Ib, Reports Fiscal Q3 Results
August 11, 2011 / Gene Silencing News
Calando Aims to Complete RNAi Phase I Trial, Ink Development Partnership by Year's End
May 19, 2011 / Gene Silencing News
'Not Happy' with Progress of Calando Phase I Solid Tumor Rx, Arrowhead Adding Third Clinical Site
February 17, 2011 / Gene Silencing News